Trial · NCT00932893
Results by group2,006
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 2,006
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) | Crizotinib | 7.7 | 95% Confidence Interval 6.0 to 8.8 | months | |
| Progression-Free Survival (PFS) | Chemotherapy | 3.0 | 95% Confidence Interval 2.6 to 4.3 | months | |
| Overall Survival (OS) | Crizotinib | 21.7 | 95% Confidence Interval 18.9 to 30.5 | months | |
| Overall Survival (OS) | Chemotherapy | 21.9 | 95% Confidence Interval 16.8 to 26.0 | months | |
| Overall Survival Probability at Months 6 and 12 | Crizotinib | Month 6 | 86.6 | 95% Confidence Interval 80.5 to 90.9 | percent chance of survival |
| Overall Survival Probability at Months 6 and 12 | Chemotherapy | Month 6 | 83.8 | 95% Confidence Interval 77.4 to 88.5 | percent chance of survival |
| Overall Survival Probability at Months 6 and 12 | Crizotinib | Month 12 | 70.4 | 95% Confidence Interval 62.9 to 76.7 | percent chance of survival |
| Overall Survival Probability at Months 6 and 12 | Chemotherapy | Month 12 | 66.7 | 95% Confidence Interval 59.1 to 73.2 | percent chance of survival |
| Percentage of Participants With Objective Response (OR) | Crizotinib | 65.3 | 95% Confidence Interval 57.7 to 72.4 | percentage of participants | |
| Percentage of Participants With Objective Response (OR) | Chemotherapy | 19.5 | 95% Confidence Interval 13.9 to 26.2 | percentage of participants | |
| Percentage of Participants With Disease Control at Week 6 | Crizotinib | 81.5 | 95% Confidence Interval 74.9 to 87.0 | percentage of participants | |
| Percentage of Participants With Disease Control at Week 6 | Chemotherapy | 55.2 | 95% Confidence Interval 47.5 to 62.7 | percentage of participants | |
| Percentage of Participants With Disease Control at Week 12 | Crizotinib | 64.2 | 95% Confidence Interval 56.5 to 71.3 | percentage of participants | |
| Percentage of Participants With Disease Control at Week 12 | Chemotherapy | 38.5 | 95% Confidence Interval 31.2 to 46.2 | percentage of participants | |
| Duration of Response (DR) | Crizotinib | 32.1 | 95% Confidence Interval 26.4 to 42.3 | weeks | |
| Duration of Response (DR) | Chemotherapy | 24.4 | 95% Confidence Interval 15 to 36 | weeks | |
| Time to Tumor Response (TTR) | Crizotinib | 6.3 | Full Range 4.4 to 48.4 | weeks | |
| Time to Tumor Response (TTR) | Chemotherapy | 12.6 | Full Range 5 to 37.1 | weeks | |
| Plasma Concentration of Crizotinib | Crizotinib | Cycle 1 Day 1 (n=15) | NA | Standard Deviation NA | nanogram per milliliter (ng/mL) |
| Plasma Concentration of Crizotinib | Crizotinib | Cycle 1 Day 15 (n=92) | 298 | Standard Deviation 148 | nanogram per milliliter (ng/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00932893/results